Edwards Lifesciences Corporation (EW)
Edwards Lifesciences Corporation reported revenue of $6.07B for the fiscal year ended Dec 31, 2025, up 11.5% from $5.44B the year before. Net income was $1.07B, a net margin of 17.7% (prior year: $4.17B). At the end of that fiscal year the company reported total assets of $13.70B and shareholders' equity of $10.34B.
Revenue
$6.07B
+11.5% vs prior year
Net income
$1.07B
Net margin 17.7%
Diluted EPS
$1.83
USD per share
Total assets
$13.70B
At Dec 31, 2025
Equity
$10.34B
At Dec 31, 2025
Shares outstanding
576M
As of Jul 31, 2026
Explore Edwards Lifesciences Corporation's filings
- Revenue by year — annual and quarterly revenue with growth rates
- Income statement & cash flow — profit, margins, EPS and operating cash flow
- Balance sheet — assets, liabilities, equity, cash and debt
- SEC filings — 10-K and 10-Q filings with links to EDGAR
Latest SEC filings
- 10-QFiled Aug 4, 2026
- 10-QFiled May 6, 2026
- 10-KFiled Feb 25, 2026
- 10-QFiled Nov 5, 2025
- 10-QFiled Aug 6, 2025
- 10-QFiled May 6, 2025
Source: SEC EDGAR XBRL company facts for CIK 1099800 (raw data). Most recent filing in this dataset: 10-Q filed Aug 4, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.